Direct-to-Consumer Genetic Testing

Abstract

This Viewpoint discusses the implications of the US FDA’s 2018 marketing authorization permitting 23and Me to market BRCA mutation testing to the general public, including concern about overtesting, false assurance, and the ability of accessible testing to improve population health outcomes.